Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance


Impaired glucose tolerance (IGT) is an increasingly frequent complication of cystic fibrosis (CF). In CF patients, a fast postprandial rise in plasma glucose is typically followed by a delayed but prolonged insulin response. Patients may develop symptoms of both hyper- and hypoglycaemia. The α-glucosidase inhibitor, acarbose, delays the hydrolysis and… (More)
DOI: 10.1007/s004310051119

4 Figures and Tables


  • Presentations referencing similar topics